The new healthcare firm will operate across the North American, APAC and European markets, which make up around 90% of the global R&D spend.

QIAGEN’s Digital Insights bioinformatics division is set to integrate NVIDIA’s accelerated computing and the BioNeMo platform to enhance AI-driven drug discovery.

Takeda has been ordered to pay $885m – potentially rising to $2.5bn – after a landmark court case verdict found the Japanese pharma company liable for a conspired arrangement ...

As China continues to inch ahead of competition in terms of trial initiations, immunology and metabolic disease trials attract sponsor eyes.

SERB Pharmaceuticals has signed an agreement to acquire exclusive development and commercialisation rights to Idefirix from Hansa Biopharma for a total of $133.6m.

The FDA has approved Daiichi Sankyo and AstraZeneca’s Enhertu for two new indications in HER2-positive early breast cancer.

Regeneron Pharmaceuticals has signed a $2.32bn deal with Parabilis Medicines to develop therapeutic candidates, with a focus on AHCs.

The UK has received doses of antiviral medicine favipiravir as a precaution in case hantavirus spreads in the country. The medicine, developed by Fujifilm subsidiary Toyama Chemical in Japan, has been ...

Kyowa Kirin has received approval from the US Food and Drug Administration (FDA) for a dosing update to the prescribing information for Crysvita (burosumab-twza), introducing a new option for adults ...

Agreement on the proposed Critical Medicines Act (CMA) represents an important step for boosting the EU pharma sector.

The wider US HHS is going through a leadership upheaval, as Republicans aim to keep voters on side amid the looming midterm elections.

Boehringer Ingelheim has received Japan’s MHLW approval for Jascayd (nerandomilast) to treat adults with IPF and PPF.